The Quantum Pharma Board has appointed Chris Rigg to the position of Chief Executive Officer (“CEO”), and to the position of non-executive chairman was named Ian Johnson.
Rigg was appointed to the Board as Chief Financial Officer (“CFO”) in March 2016 and has been Acting CEO since 1 August 2016. The Board has commenced a formal search process for a new CFO but, in the interim, as well as permanent CEO, Chris will remain as CFO until a replacement for that role is appointed.
Furthermore, Christopher Mills was named a non-executive Director and Dr John Brown as Senior Independent non-executive Director. The Company’s Board has started a formal search process for a further non-executive Director. John Clarke and Sheila Kelly, non-executive Chairman and non-executive Director respectively, have resigned from their positions on the Board with immediate effect to focus on other Directorships and new business appointments.